Resultats de la cerca - Renáta Váraljai

  • Mostrar 1 - 7 resultats de 7
Refinar resultats
  1. 1
    Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells

    Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells per Renáta Váraljai, Abul Bashar Mir Md. Khademul Islam, Michael L. Beshiri, Jalees Rehman, Núria López-Bigas, Elizaveta V. Benevolenskaya

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Honokiol is a FOXM1 antagonist

    Honokiol is a FOXM1 antagonist per Marianna Halasi, Ben Hitchinson, Binal N. Shah, Renáta Váraljai, Irum Khan, Elizaveta V. Benevolenskaya, Vadim Gaponenko, Jack L. Arbiser, Andrei L. Gartel

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

    RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melan... per Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Rahayu Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael J. Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma

    Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma per Renáta Váraljai, Kilian Wistuba‐Hamprecht, Teofila Seremet, Joey Mark S. Diaz, Jérémie Nsengimana, Antje Sucker, Klaus Griewank, Jan‐Malte Placke, Péter Horn, Nils von Neuhoff, Batool Shannan, Heike Chauvistré, Felix C. E. Vogel, Susanne Horn, Jürgen C. Becker, Julia Newton‐Bishop, Andreas Stang, Bart Neyns, Benjamin Weide, Dirk Schadendorf, Alexander Roesch

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

    Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma per Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

    Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma per Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, Paulien Kaptein, Lea Jessica Albrecht, Batool Shannan, Jan C. Brase, Daniel Gusenleitner, Teresa Amaral, Nina Wyss, Jochen Utikal, Lukas Flatz, Florian Rambow, Hans Christian Reinhardt, Jenny Bottek, Daniel R. Engel, Susanne Horn, Selma Ugurel, Wiebke Sondermann, Elisabeth Livingstone, Antje Sucker, Annette Paschen, Fang Zhao, Jan M. Placke, Jasmin Klose, Wolfgang P. Fendler, Daniela S. Thommen, Iris Helfrich, Dirk Schadendorf, Alexander Roesch

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Persister state-directed transitioning and vulnerability in melanoma

    Persister state-directed transitioning and vulnerability in melanoma per Heike Chauvistré, Batool Shannan, Sheena M. Daignault-Mill, Robert J. Ju, Daniel Picard, Stefanie Egetemaier, Renáta Váraljai, Christine S. Gibhardt, Antonio Sechi, Farnusch Kaschani, Oliver Keminer, Samantha J. Stehbens, Qin Liu, Xiangfan Yin, Kirujan Jeyakumar, Felix C. E. Vogel, Clemens Krepler, Vito W. Rebecca, Linda Kubat, Smiths Lueong, Jan Förster, Susanne Horn, Marc Remke, Michael Ehrmann, Annette Paschen, Jürgen C. Becker, Iris Helfrich, Daniel Rauh, Markus Kaiser, Sheraz Gul, Meenhard Herlyn, Ivan Bogeski, José Neptuno Rodrı́guez-López, Nikolas K. Haass, Dirk Schadendorf, Alexander Roesch

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: